Tesamorelin

$45.00


Tesamorelin synthetic GHRH analog available in a 10 mg research format with lot-specific analytical documentation. Strictly for laboratory research use only. Not for human or veterinary use.

Available

Order within –h –m –s to ship on Monday, November 16.
10:00 AM ET cutoff • In-stock products only
Choose purchase type

LOT-SPECIFIC TESTING

Verified Test Results


Lot-Specific COA

Parameter Result Specification
Appearance


Good

Meets spec
Purity


98.76%
· Pass

≥ 95%
Net Peptide Content


11.12mg

Reported
Identity


Confirmed

Meets spec
Fentanyl Screen


Not Detected

Pass
Heavy Metals


Not Detected

Pass
Sterility


No Growth

Pass
Lot
TE10-0618
Laboratory
Janoshik Analytical

Results shown apply to the listed product lot. Review the full certificate for complete testing information.

Description

Tesamorelin Research Peptide

Tesamorelin is a synthetic 44-amino-acid analog of growth hormone-releasing hormone, commonly abbreviated as GHRH. Published research has examined tesamorelin in relation to pituitary signaling and the growth hormone and insulin-like growth factor 1, or GH/IGF-1, axis.

East Coast Peptides offers tesamorelin in a 10 mg research format supported by lot-specific analytical documentation. This material is supplied exclusively for controlled laboratory investigation and is not intended for human or veterinary use.

Tesamorelin and GHRH Research

Naturally occurring GHRH is involved in signaling between the hypothalamus and anterior pituitary gland. Through interaction with GHRH receptors on pituitary somatotroph cells, it participates in the regulation of pulsatile growth hormone release. Growth hormone can subsequently influence downstream IGF-1 signaling and other endocrine pathways.

Published tesamorelin research has evaluated endpoints including growth hormone pulsatility, IGF-1 concentrations, adipose-tissue measurements, lipid markers and glucose-related variables. Some studies used randomized, placebo-controlled clinical designs involving adults with HIV-associated central fat accumulation. Other work has investigated the relationship between changes in visceral adipose tissue and liver-fat measurements within similarly defined populations.

These clinical findings require careful interpretation. They concern regulated pharmaceutical tesamorelin formulations used under controlled medical-study conditions in specific patient populations. They do not establish general weight-loss, muscle-building, performance, anti-aging or body-composition outcomes, and they should not be attributed to the East Coast Peptides research product.

The ECP product is laboratory research material and is not the branded prescription medication. Researchers should verify the identity and specifications of the current lot and use independently validated analytical or experimental methods appropriate to their research question.

Selected Research References

Product Information

  • Product: Tesamorelin research peptide
  • Compound type: Synthetic GHRH analog
  • Length: 44 amino acids
  • Format: 10 mg
  • Documentation: Lot-specific analytical results are available through the ECP COA Catalog.
  • Intended application: Laboratory research only

Continue Your Research

Explore evidence-aware compound overviews, comparisons, and laboratory research topics in the ECP Research Blog.

Research Use Notice

This product is sold exclusively for laboratory and research use. Not for human or animal use. It is not intended to diagnose, treat, cure, or prevent any disease. No medical or therapeutic claims are made or implied.

Reviews

There are no reviews yet.

Be the first to review “Tesamorelin”

Your email address will not be published. Required fields are marked *

This product is currently sold out. Don't worry! Enter your email and we'll notify you when it's available again.